Search PubMed⌕ Search

Biomedical subjects

F Zintl

Publications and source records attributed to F Zintl.

At least 145 records · Page 8Linked to original sources
PubMed1978

[Serological diagnosis of the antigenic markers of acute lymphatic leukaemias and non-Hodgkin lymphomas in childhood (author's transl)].

Leukaemia cells of 11 children with acute lymphatic leukaemias (ALL) and lymphoma cells of 4 children with lymphosarcoma (LS) were studied for the presence of T- and B-lymphocyte markers on their cell membranes. Spontaneous rosette formation (E-rosettes) of the malignant cells after adding sheep erythrocytes and the reaction with antithymocyteserum in cytotoxic test served as T-cell-markers and the surface immunoglobulins as B-cell-markers. The leukaemia cells of 5 ALL-patients with mediastinal tumours formed E-rosettes and reacted with the anti-thymocyte-serum. Six ALL-patients did not show these reactions. None of the ALL-patients had surface-immunoglobulins. Two of the 4 LS-children were E-rosette-positive, the cells of the other two LS-children contained surface immunoglobulins. There was a good correlation between the formation of E-rosettes and the reaction with the anti-thymocyte-serum. After absorption of the anti-thymocyte-serum with peripheral leukocytes it reacted with some of the E-positive lymphoblasts and thymocytes but not with normal peripheral T-lymphocytes. Anti-leukaemia-sera against the ALL-cells with T-cell markers of two patients after absorption with spleen cells did not react with peripheral lymphocytes but did effect lysis of thymocytes. Consequently, leukaemia cells which are E-rosette-positive possess a T-lymphocyte-associated antigen and a Thymus-associated antigen.

Adolescent↗
PubMed1978

[Complement activity in leukemic patients].

The in vitro test of heterologous anti-leukaemic sera against human leukaemic cells resulted in the serum of leukaemic patients being able to produce a lysis of leukaemic cells in the leukaemic phase as well as in remission when specific heterologous antibodies were present.

Antibody Specificity↗
PubMed1978

Specificities of heterologous antisera against human leukaemia cells. 1. Reactions against leukaemia cells.

Rabbit or goat antisera directed to ALL, CLL, AML and CML cells were investigated in cytotoxicity tests with different leukaemia and normal cells as targets. After absorptions with erythrocytes and spleen cells from allogeneic donors the antisera killed only leukaemia cells. There was no reaction with remission leukocytes or blood leukocytes from normal donors. Anti-ALL-Sera reacted in 35 out of 49 tests with ALL cells from 13 patients. Apparently the ALL antisera which were directed to the T cell subtype of ALL preferentially affected ALL cells of this subtype. Cross reactions with cells from CLL, AML and CML were not found. Anti-CLL-sera reacted in 10 out of 12 tests with CLL cells from 4 donors, and in 4 out of 20 tests with ALL cells from 7 donors and also with the cells of a CML patient. AML cells from two patients were not killed. Antisera against AML and CML showed extensive cross reactions with cells of myelocytic and lymphocytic leukaemias. Absorption tests demonstrated the presence of two antibody specificities in AML antisera, one of which being directed to a common antigen of AML and ALL cells and another against an antigen of myelocytic leukaemia cells.

Antibodies, Neoplasm↗
PubMed1978

Specificities of heterologous antisera against human leukaemia cells. 2. Reactions against fetal liver cells and absorption studies with fetal tissue.

Rabbit or goat antisera directed to ALL and AML cells were investigated in cytotoxicity tests with fetal liver cells as targets. After absorption with erythrocytes and spleen cells from allogenic donors the antisera killed fetal liver cells. There was no reaction with remission leukocytes or blood leukocytes from normal donors. Treatment with fetal tissue removed the activity of the AML and ALL antisera against ALL cells but not of the AML antisera against AML cells. This indicates the existence of at least two antigens on the surface of AML cells, one antigen is common with ALL cells and of fetal origin and another one seems to be characteristic of AML cells and not of fetal origin. Because treatment with fetal tissue removed all activity of the ALL antisera it can be assumed that leukaemia-associated antigens on ALL cells are of fetal origin.

Antibody Specificity↗
PubMed1977

[Immune defect diseases in childhood].

The immune reactions of man may be subdivided into two main types, the antibody-bound and the cell-bound immunity. The effect of these two systems is realised by two different lymphocyte populations: T- and B-cells, which may show isolated or combined congenital defects and are known as primary immune defects. Antibody deficiency diseases are the by far most frequent congenital diseases. Concerning the frequency the combined and cellular immune defects follow. At present the diagnostic possibilities are already largely developed. Immune defect diseases have much contributed to the understanding of the normal immune reactions. Though these diseases also nowadays still have an extremely bad prognosis, there exists already for some forms a therapy in form of the transplantation of bone marrow, which is able to restore the defect immune system.

Adolescent↗
PubMed1976

[Diagnostic and therapeutic aspects of leukoses in childhood].

30 TO 40% of all malignant neoformations in childhood are leukaemias. Within this group 80 to 85% of acute lymphatic leukaemias are found. The indicating signs (conditioned by the suppression of the normal myelopoiesis) are briefly described, differential diagnosies are only mentioned. Primary diagnostics and diagnostics of the course, the principles of remission induction and continuous therapy in leucaemia are sketchily described. Treatment of acute lymphatic leukaemia is performed adequate to the therapeutic scheme after Pinkel Prophylaxis of the central nervous system must be demanded. Modern therapeutic methods with the help of synchronisation and oncobiogramme are demonstrated. The possibilities of the symptomatic therapy in disease-conditioned and therapy-conditioned complications and side-effects occupy a somewhat broader space. Finally the principles of the organisation of the treatment of leukaemia in childhood are described.

Age Factors↗
PubMed1976

[Prerequisites and possibilities of immunotherapy in acute leukemias].

Nowadays there are references that immuno-reactions of patients with carcinoma against tumour-associated antigens are of essential significance for the development and progressing of tumours. Also the frequent appearance of neoplasms in primary immunodeficiency syndromes indicates this fact. Also in human leukaemias there exist leukaemia-associated antigens. Humoral as well as cell-bound immunoreactions may be proved. Possibly leukaemia-associated immunoglobulins are blocking factors which prevent the cellular immunoreactions against leukaemia-associated membrane antigens. The presence of specific reactions against antigens on leukaemia-cells was the condition for a successful immunotherapy. Despite many theoretical possibilities the immunotherapy in the clinic at present restricts to the BCG-vaccination and to the application of living or irradiated leukaemia-cells. The hitherto reported results are encouraging.

Acute Disease↗
PubMed1976

[Studies on the epidemiology of malignant tumors, systemic diseases and leukemia in children (author's transl)].

The analysis of statistical data on the incidence of leukemia in children in the German Democratic Republic between 1968 and 1973 gives no evidence for increasing risk of disease. Incidence in the G.D.R. is about the same as reported in literature. It seems that in the etiology and natural history of malignant tumors and hemoblastosis in children, constitutional and genetic as well as environmental factors are involved. They may work single or combined. Probably, malignant tumors or malignant systemic disease arise if the immune system fails to destroy endogenous or transplanted tumor cells.

Adolescent↗